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Abstract
Background: To complete a systematic review and meta-analysis based on the clinical question:
Is Deflazacort (DFZ), a prednisolone derivative, an effective therapy for improving strength, with
acceptable side effects, in children with Duchenne Dystrophy (DD)?
Methods:  MEDLINE, EMBASE, Current Contents, Dissertation Abstracts, Health Star,
PsychINFO and Cochrane, were searched using the following inclusion criteria: 1) A randomized
controlled trial comparing DFZ with placebo or another therapy; 2) Male participants age 2–18
years with DD; 3) Outcomes of (a) any form of strength or functional testing, or (b) any form of
side effect.
Results: Fifteen studies of potential relevance were identified, with five meeting the inclusion
criteria. These five studies included 291 children and were published in English language journals
between 1994 and 2000. Two studies compared DFZ versus placebo, two studies compared DFZ
with prednisone and one study had both placebo and prednisone comparisions. Two large trials
were identified that have not been published in article format. Due to the heterogeneity in outcome
measures and the inconsistent reporting of summary statistics a meta-analytic approach could not
be taken.
Conclusions: Examining individual studies it appears that DFZ improves strength and functional
outcomes compared to placebo, but it remains unclear if it has a benefit over prednisone on similar
outcomes. Two trials found that DFZ causes less weight gain than prednisone.
Background
Duchenne Dystrophy (DD) is a chronic degenerative
muscle disorder that becomes evident in mid-childhood.
Several therapies have been examined with the aim of
slowing the progression of muscle weakness in children
with DD. Corticosteroids have been the drug of main
interest with prednisone demonstrating evidence of
improvement in some patients and a lack of deterioration
in others [1]. Multiple randomized trials have found
improved function and strength in children treated with
prednisone [2–5]. Unfortunately, in these studies pred-
nisone had a great deal of side effects which may temper
its usefulness. A methyloxazoline derivative of pred-
nisolone, deflazacort (DFZ), has shown some promise in
providing similar effects to prednisone with a less con-
cerning side effect profile [6,7]. If both drugs are similarly
effective in improving strength, and if weight gain is less
evident with DFZ then improvements in functional
strength may exceed those seen with prednisone. A recent
call has been noted for a systematic examination of the
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evidence for the effectiveness and safety of DFZ in the DD
population [8].
Thus, the clinical questions that arise are whether DFZ is
an effective therapy for improving strength in children
with DD?; is DFZ more effective than other therapies?;
and, does DFZ have fewer side effects than other steroid
agents used in the treatment of DD? This systematic
review attempted to answer these queries by identifying
randomized controlled trials of DFZ in the DD popula-
tion with the goal of completing a meta-analysis of the
treatment effects and safety profile.
Methods
The review was conducted adhering to the principles of
the QUORUM statement [9]. The techniques for identify-
ing relevant studies included several different procedures.
First, electronic database sources were searched using
Ovid without restriction on language or publication sta-
tus. The original search strategy is given in Appendix A
[see Additional file 1]. At first, the search included specif-
ics to identify randomized trials but, the search was broad-
ened to find any articles with the population terms
"Duchenne muscular dystrophy", "muscular dystrophy"
or "myopathy" and the treatment terms "deflazacort",
"21-deacetyl deflazacort" or "steroid". The databases
search included: MEDLINE (1966-Week 4 2002),
EMBASE (1974–2002, week 19), Current Contents (1993-
Week 14 2002), Dissertation Abstracts (1861-Feb 2001),
Health Star (1987-Jan 2002), PsychINFO (1887–2002).
The Cochrane Controlled Trials Register (issue 2, 2002)
was searched and served as a surrogate hand search.
Because of few identified studies during each search the
abstracts were accessed and reviewed for relevancy at the
time of the search.
Second, reference lists from the selected trials were
reviewed as well as reference sections from textbooks and
review articles. Third, four content experts were contacted
to try to identify unpublished trials. Finally, the company
that is manufacturing DFZ for use in Canada, Aventis, was
contacted to identify trials that were conducted internally.
Trial Selection
The authors assessed the title and abstract during the
searches and retained references that appeared relevant.
Every effort was made to be liberal in the approach to ref-
erence selection. A similar approach was taken with refer-
ence list searching. Once a reference was selected the full
text article was obtained and assessed for eligibility
criteria.
Trials were eligible for inclusion in the systematic review
if they met the following criteria: 1) A randomized con-
trolled trial comparing DFZ with placebo or another
standard therapy; 2) The participants were male children
age 2–18 years with genetic or muscle biopsy proven DD;
3) The outcome measure was either (a) any form of
strength testing, including functional testing, or (b) any
form of side effect.
Trial Quality
All trials meeting eligibility criteria were then assessed for
quality using two measures. The first was the Jadad scale
[10], which assigns one point each for a trial described as
1) randomized, 2) double-blind, and 3) that outlines
withdrawals and drop-outs. An additional point is given if
the method of randomization and double-blinding (one
point each) is described and is correct and conversely a
point is deducted for each aspect if the method is incor-
rect. A total score of five is possible with a score of three or
greater considered high quality. The second was a rating of
treatment allocation concealment including three catego-
ries: adequate concealment, inadequate concealment and
unclear [11]. The quality ratings were done by both
authors independently and one author (PJ) was blinded
to the study authors and journal of publication. The Jadad
scale and rating of allocation concealment were applied to
abstracts, as well, recognizing that these scales have not
been developed nor validated for this purpose but finding
no other suitable way to assess the quality of abstracts.
Data Abstraction
One author (CC) reviewed all studies meeting eligibility
criteria and abstracted data in the following areas: study
description (language, year, centres, publication status,
funding source); trial design (design, quality, sample
size); population (method of diagnosis, age, stage of dis-
ease at baseline); intervention (dosage, timing, duration,
compliance, co-interventions); comparitor (placebo vs.
drug, dose, timing, duration); outcomes (strength meas-
ures, task speed, change over baseline); adverse effects
(frequency and severity of weight gain, osteoporosis, cata-
ract, etc.).
In cases where little numerical data was presented the
study authors were contacted and asked to provide quan-
titative summary data with standard deviations. In cases
where no standard deviations were given these were
imputed based on presented p values assuming they were
derived by t tests with common variance.
Outcomes
Outcome data included any measure of strength and
included direct muscle strength testing, timed functional
tasks and time to loss of ambulation. Outcomes in trials
comparing DFZ to placebo were examined separately
from those comparing DFZ to another steroid. Data for
side effect and safety assessment was primarily focused onBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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weight gain, however, other side effects were included
when reported.
Sensitivity, Subgroup Analysis and Publication Bias
In the initial planning of the systematic review the goal
was to explore differences in trials with respect to quality
and design characteristics such as blinding. A secondary
goal of the review was to present findings in different age
groups and stages of disease. Due to the relatively few
studies and lack of presentation of data amenable to such
analysis this aspect was unable to be completed.
The assessment of publication bias was abandoned given
the identified publication issues in this particular group of
studies. This will be discussed further in the results and
discussion.
Results
The citations identified during the various search tech-
niques are presented in Table 1. For electronic database
searching a broad search strategy was used, as a narrow
search strategy (including filters for randomized trials)
identified very few studies to review. Reassuringly,
although the broad search strategy in MEDLINE elicited
15 times more studies initially, the exact same relevant
studies were identified using both techniques. As might be
expected by its thorough hand searching techniques, the
Cochrane Library was the most fruitful database to search
and had the highest ratio of identified citations to poten-
tially relevant studies. Cochrane searching also identified
four abstracts, none of which were identified in other
searches.
Searching article and textbook reference lists identified
two additional references, however neither resulted in
studies meeting eligibility criteria. Two of four content
experts responded to our correspondence, with one iden-
tifying a study not previously identified via other meth-
ods. Aventis did not know of any trials, conducted or
sponsored, that were not already in the literature.
After eliminating duplicate studies identified via different
search techniques 15 studies of potential relevance were
collected in full text and the study characteristics are listed
in Table 2. One non-English language trial was not
retrieved (Study J) but this was not based on the language
of publication but rather that it appeared to be a prelimi-
nary report on a trial that was also published several times
in English (Studies D, H, L and O). Ultimately, five of
these studies met the inclusion criteria (Studies A, B, F, G
and N). Inclusion criteria violations are reported for the
other 11 studies in Table 2.
Table 1: Search Results
Source Search 
Strategy
Number of 
citations identified
Number of 
Potentially 
Relevant Studies
Study Label Total number of Different 
studies identified
Electronic Data Base Search
MEDLINE narrow 17 5 A, B, C, D, E N = 12
EMBASE narrow 55 5 A, B, C, H, O N = 12
MEDLINE broad 241 5 A, B, C, D, E N = 12
Current Contents broad 83 0 N = 12
HealthStar broad 60 4 A, B, C, D N = 12
Psychlit broad 2 0 N = 12
Dissertation Abstracts broad 1 0 N = 12
Cochrane broad 10 10 A, B, C, D, F, G, H, I, J, K N = 12
Reference List Search *
3 L, M N = 2
Expert Correspondence and Pharmaceutical Company Contact *
1 N N = 1
Total Number of Potentially Relevant Studies Identified N = 15
* These totals are excluding those studies already identified via electronic searchesBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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The characteristics of the studies meeting inclusion criteria
are presented in Table 3. The included studies were pub-
lished between 1994 and 2000. All were published in Eng-
lish language journals, with three of the five reports
appearing in one journal. Three of the trials described
being double blind while two others had no mention of
blinding at all. None of the trials provided information on
pre-defined clinically important differences expected or
on sample size calculations. One trial used 2:1 randomi-
zation into treatment and control groups respectively but
no reason for this design was provided. One trial used a
four-arm randomization with placebo, prednisone and
two doses of DFZ. In that study, the placebo group was
dismantled at three months and these patients were re-
randomized into the other arms.
A total of 291 patients were randomized, however,
because two trials did not specify the size of the groups it
is not clear how many received treatment compared to
control. One trial made up 73% (n = 196) of the total par-
ticipant number. Four of the trials included appeared to
arise from one group of investigators and these appeared
to be financially supported by the same agency.
The Jadad scale score and allocation concealment status is
given in Table 3. Quality assessment was consistent
between authors with identical scores on four of five stud-
ies. The disagreement came on the description of drop-
outs in study B with one author assigning no point and
the other one point. Following review of the article the
consensus was that an adequate account had been given
in the text regarding dropouts and the study was given one
point for this criterion. Two studies received a score of 3
on the Jadad scale. None of the studies made any com-
ment on allocation concealment techniques. Attempts to
clarify methodological information from the authors of
the two studies found only in abstract form were
unsuccessful.
The dose of DFZ was relatively uniform over the four trials
ranging between the equivalent of 0.9 and 1.2 mg/kg each
day. In only one trial was any mention made of co-inter-
ventions and in this case it was dietary advice to help con-
trol weight gain. Three trials compared DFZ to
prednisone. Of these, two trials reported follow-up data to
12 months and one until three months. Three trials com-
pared DFZ to placebo. One had 24 months follow-up,
however, marked drop out occurred in the second year so
reliable data was only available until the 12 month time
period. The second trial comparing placebo to DFZ was
the four-arm trial (Study N) but because of substantial dif-
ferences found in strength which was in favor of steroids
the placebo arm was discontinued at three months time.
Fourteen different strength measurements were used in
the four trials. As anticipated, three major categories of
testing were evident: (1) Direct strength measures, (2)
Functional measures and (3) Time to loss of ambulation.
Table 4 describes each outcome measure and in which
study it was used.
Table 2: Study Characteristics
Study No. Author (s) Year Source Publication Status Inclusion Criteria 
Met
Reason for Exclusion
A Bonifati et al. [19] 2000 Muscle and Nerve Article Yes -
B Angelini et al. [20] 1994 Muscle and Nerve Article Yes -
C Mesa et al. [21] 1991 Neuromuscular Disorders Article No Not randomized.
D Reitter [22] 1995 Brain and Development Article No Interim report of a trial. No 
results by treatment given.
E Luz et al. [23] 1982 Revista Chilena de Pediatria Article No Not randomized.
F Angelini et al. [24] 1998 Muscle and Nerve Abstract Yes -
G Angelini et al. [25] 1995 Neurology Abstract Yes -
H Reitter [26] 1995 Developmental Medicine 
and Child Neurology
Abstract No Interim report of a trial. No 
results by treatment given.
I Winter et al. [27] 1999 Acta Myologica Article No No strength or side effect 
data reported.
J Rietter [28] 1995 Monatsschrift fur 
Kinderheilkunde
N/A N/A Not retrieved. Felt to be a 
duplicate publication.
K Todorovic et al. [29] 1998 Muscle and Nerve Abstract No DFZ not used.
L Reitter [13] 1998 Neuromuscular Disorders Meeting Proceeding No Report of randomized trial 
but no specific outcomes 
reported.
M Dubrovsky et al. [30] 1999 Neurology Abstract No Not randomized
N Brooke [12] 1996 Neurology Abstract Yes -
O ENMC Workshop [31] 1997 Neuromuscular Disorders Meeting Proceeding No Report of randomized trial 
but no specific outcomes 
reported.
ENMC = European Neuromuscular CentreBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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The results of the three trials comparing DFZ and pred-
nisone are given in Table 5. Not one measure of strength
overlapped between studies. Only two studies reported
numerical forms of summary statistics but none of the
studies reported standard errors. Only one study provided
p-values for statistical significance but these were for the
steroid groups versus placebo. In this case standard errors
were imputed, and sample size had to be estimated, but
given the similarity between the point estimate for mean
change in strength between the placebo and prednisone
group the standard errors would have had to be quite
small to invoke comparing the values through a t-test.
Because of the limited data and heterogeneity in strength
measures meta-analysis could not be performed. Two of
the studies were presented in the form of abstracts and
this may have limited the ability to present appropriate
figures for meta-analysis. The author of the largest study
was contacted in order to obtain original data but indi-
cated that the data was unavailable for analysis.
Similar difficulties arose in comparing the results in the
three studies using placebo as the control as seen in Table
6. Although one study used a wide array of strength
measures and included standard errors and p values, the
other studies only provided point estimates or no numeric
values. Attempts to convert the data to mean percentage
change from baseline were not successful, as one study did
not present the baseline values. Again, it was impossible
to use this data for meta-analysis. The results from Study
B provided the most thorough and convincing evidence
for the superiority of DFZ to placebo. In seven of the 11
tests performed to measure strength there was a significant
difference in favor of DFZ and in the other four tests not
reaching statistical significance, the point estimates for
change from baseline all favored DFZ. The most clinically
important result was the 12.7 month difference in time to
wheel chair use between the groups.
Table 7 outlines the five studies that reported on side
effects. Measures of side effects focused on weight gain, as
expected, but other documented side effects included
osteoporosis, hirsuitism, cushingoid appearance, increase
appetite, behavior changes and cataract formation. All five
studies commented on weight gain. Two studies did not
find a significant mean difference in weight gain com-
pared to placebo but did not present the numerical values.
This result was surprising, as these studies compared DFZ
to placebo. The other two studies found that there was an
11.3 % and 8.4% difference in mean weight gain (as
expressed as a percentage increase from baseline weight)
between DFZ and prednisone groups, favoring DFZ. The
final study reported the difference between prednisone
and DFZ as minimal. No standard errors were presented
in these studies and in one study group sizes were
unknown so these results were not combined using meta-
analytic techniques.
Discussion
This review included five randomized controlled trials
comparing DFZ treatment to a control group. One further
Table 3: Trial Meeting Inclusion Criteria: Characteristics and Quality Assessment
Study A. Bonifati, 2000 B. Angelini, 1994 F. Angelini, 1998 G. Angelini, 1995 N. Brooke, 1996
Design RCT RCT 2:1 treatment to 
controls
RCT RCT 4 arm RCT 1. Placebo 2. 
Prednisone 3. DFZ low 
dose 4. DFZ high dose
Blinding Double blind Double blind Not mentioned Not mentioned Double blind
Jadad Score 331 0 2
Allocation 
Concealment
Not stated Not stated Not stated Not stated Not stated
Sample size: 
Treatment
18 patients total 
randomized
17 13 14 196 patients total 
randomized
Sample Size: Controls Unclear 11 13 9 Unclear
Treatment dose 0.9 mg/kg/day 2 mg/kg/dose on alternate 
days
1 mg/kg/day 1. DFZ 1 mg/kg/day for 6 
months then 2 mg/kg/dose on 
alternate days 2. DFZ 2 mg/
kg/dose on alternate days
Low dose = 0.9 mg/kg/day 
High dose = 1.2 mg/kg/day
Comparator (dose of 
active control
Prednisone (0.75 mg/kg/
day)
Placebo Prednisone (0.75 mg/kg/
day)
Placebo 1. Placebo 2. Prednisone 
(0.75 mg/kg/day)
Mean age at baseline Treated 8.6 y Controls 
7.5 y
Treated 98.65 m Controls 
96.55 m
Not stated Not stated Not stated
Disease Status at 
baseline
1. Ability to walk 2. No 
prior steroids
Ability to walk Not stated Not stated Not stated
Co-interventions Not stated Diet advice Not stated Not stated Not stated
Duration of Follow-up 
(months)
12 months 24 months (Data taken at 
12 months due to 
excessive drop out after 
this time)
12 months Not stated 1. 3 months for placebo 
vs. DFZ 2. Efficacy: 3 
months for prednisone vs. 
DFZ 3. Side Effects: 12 
months for prednisione 
vs. DFZBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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RCT was identified (study D, L, H, O and likely J) but was
not included because the outcomes have never been pub-
lished. These six studies have included 391 participants in
at least three different countries. Unfortunately, the two
largest trials, including 196 [12] and 100 [13] patients
have never been published in journal article format for
peer review. The first of these two trials (Study N) was
published in abstract form but, as was demonstrated in
Table 5 and 6, the reporting of the trial in this format did
not allow the reader to gain insight into the efficacy of
DFZ. The second large trial (Study D, H, L, O, and likely
J), a multi-centre study, was last reported on in 1998 and
compared prenisolone with DFZ. At the time of the meet-
ing proceeding the randomization code had been broken,
however, the proceeding gave no numeric indication of
the results and suggested that "both steroids slowed the
degradation equally well"[13]. The investigator of this
study confirmed that the results remain unpublished and
that data is not currently available for use in meta-analy-
sis.
The fact that data remains unpublished from these two tri-
als is an unfortunate situation from both a clinical and a
research ethics perspective. As this review has demon-
strated, there is no convincing body of evidence to sup-
port the superiority or, on the other hand, the equivalence
of prednisone and DFZ for improving or maintaining
strength or function in children with DD. This issue
would certainly be clarified by publication of this data.
Access to DFZ is difficult in Canada and the United States
as there is currently very little information to support its
use. From an ethical perspective, participants in research
studies deserve that the results of their outcomes in trials
will be used to improve care for others in similar circum-
stance. In this scenario the participants have not been well
served for the risks they incurred by entry into the studies.
From a methodologic perspective, the findings of this
review support the belief that unpublished data should be
sought and included in systematic reviews and meta-anal-
yses [14].
Of the studies eligible under the criteria and mandate of
this review, only one study provided evidence of the effi-
Table 4: Outcome Measures.
Outcome Measure Description Used in Study
Direct Strength Measures
Myometer Isometric force of quadriceps femoris muscle at 90° measured in kg. [32] B
MRC score The sum of MRC scale in four muscles. Two in the right upper extremity and two in the right 
lower extremity. Maximum score 20. [32]
A, G
MRC index The MRC score divided by the maximum possible score of 20 then multiplied by 100 to give a 
percentage representation of the MRC score. [32]
B
Average muscle score Called Strength score in previous trials.[33] This is the mean grade of 34 tested muscles on a 
ten point scale (modified from the MRC system).
N
Functional Measures
Timed gait Number of seconds needed to walk for 10 metres. A, B
Timed stairs Number of seconds needed to walk up four stairs. A, B
Timed chair Number of seconds needed to rise from seated in a chair to standing. A, B
Timed Gower Number of seconds needed to rise from a sitting position on the floor to standing. A, B
Graded gait A score assigned for 10 m of walking. Points assigned for increasing dysfunction for a range 
between zero and seven. [32]
A, B
Graded stairs A score assigned for walking up four stairs. Points assigned for increasing dysfunction with a 
range between zero and seven. [32]
A, B
Graded chair A score assigned for rising from a chair to standing. Points assigned for increasing dysfunction 
with a range between zero and six. [32]
A, B
Graded Gower A score assigned for rising from a sitting position to standing. Points assigned for increasing 
dysfunction with a range between zero and seven. [32]
A, B
Others
Patient reported benefit No description of measure available. F
Time to loss of ambulation Measured in months. B
MRC = Medical Research CouncilBMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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cacy of DFZ (Study B). This study had a placebo control
and used 11 different methods of measuring efficacy. The
sample size was relatively small, 28 patients total, but was
able to demonstrate significant differences between pla-
cebo and DFZ on seven of 11 strength measures. The other
four tests all showed point estimates favoring DFZ. The
second study demonstrating efficacy of DFZ over placebo
(study N) followed the placebo group for only three
months and the third study in this groupclaimed an
improvement in strength. Unfortunately, given the mini-
mal information in these latter two studies the results
could not be synthesized by meta-analysis. The evidence
from these three randomized trials suggests a clinically
and statistically significant benefit on measures of
strength with the use of DFZ compared to no treatment
(placebo).
The other eligible studies (study A, F, and N) all compared
DFZ to prednisone, and as demonstrated in Table 5 and
discussed in the result section, no reasonable conclusions
can be drawn from these studies. None of the studies
described what was considered a minimal clinically
important difference or the power of the study to detect it.
All the authors concluded that there was no substantial
difference between DFZ and prednisone with one author
(study A) stating that the two therapies were equally
effective.
Weight gain was the side effect which received the most
focus in the studies examined. Two studies (study A and
N) provided numerical comparisons with statistical tests
comparing the mean weight gain as a percentage of
baseline weight. These two studies both found an approx-
imately ten percent difference in weight gain favoring DFZ
over prednisone. No age by treatment or severity by treat-
ment effects are reported to determine who is at the great-
est risk for weight related problems. Thus, the evidence
from these two trials show that weight gain is less of a
problem on DFZ and this should be considered in thera-
peutic decisions. Unfortunately the incidence of side
effects was infrequent and not often reported by treatment
group making conclusions difficult. A body of anecdotal
and observational literature exists regarding side effects
Table 5: Strength Outcomes. Studies Comparing Deflazacort and Prednisone.
Study (Duration of Follow up) A. Bonifati, 2000 (12 months) F. Angelini, 1998 (12 months) N. Brooke, 1996 (3 months)
Strength Measures
MRC score * (mean change in 
score from baseline)
DFZ: + 1 Pred: + 0.5 No 
variance or P values reported.
--
Average Muscle score * (mean 
change in score from baseline)
- - DFZ (low): +0.18 (+/- 0.4) DFZ (high): 
+0.26 (+/- 0.5) Pred: +0.27 (+/- 0.5) 
Standard errors imputed from p values.
Functional Measures
Timed gait Measured but not reported. - -
T i m e d  s t a i r s ---
T i m e d  c h a i r ---
T i m e d  G o w e r ---
Graded gait ** DFZ: - 0.5 Pred: -0.5 
Combined score from all four 
tests. No variance or p values 
reported.
--
Graded stairs ** - - -
Graded chair ** - - -
Graded Gower ** - - -
Other Measures
Patient reported benefit - Patients reported benefit on 
both prednisone and DFZ. No 
numeric representation of 
reported benefit was reported.
-
A dash represents that this outcome measure was not used. MRC = Medical Research Council * For MRC score, MRC index and muscle score 
higher scores are more favorable. ** For Graded scores a lower score is more favorable.BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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Table 6: Strength Outcomes. Studies Comparing Deflazacort and Placebo.
Study (Duration of Follow up) B. Angelini, 1994 (12 months) G. Angelini, 1995 (Not stated) N. Brooke, 1996 (3 months)
Strength Measures
Myometer (difference from baseline) DFZ: 1.78 +/- 2.42 kg Placebo: 0.44 +/- 1.37 kg p 
value: NS
--
MRC score - Improvement in MRC score in 
both daily and alternate day 
groups. No numerical values given.
MRC index * (difference from 
baseline)
DFZ: -2.35 +/- 5.48 Placebo: -9.77 +/- 12.62 p < 0.05 - -
Average muscle score * (difference 
from baseline)
- - DFZ (low): +0.18 (+/- 0.4) DFZ (high): 
+0.26 (+/- 0.5) Placebo: -0.1 (+/- 0.5) p < 
0.0001 Standard errors imputed from p 
values.
Functional Measures
Timed gait (difference from baseline) DFZ: -0.46 +/- 1.66 Placebo: 2.00 +/- 2.54 p < 0.01 - -
Timed stairs (difference from 
baseline)
DFZ: -1.79 +/- 4.23 Placebo: 3.71 +/- 4.64 p < 0.01 - -
Timed chair (difference from 
baseline)
DFZ: -0.43 +/- 2.65 Placebo: 2.33 +/- 5.20 P value NS - -
Timed Gower (difference from 
baseline)
DFZ: 1.81 +/- 7.18 Placebo: 3.33 +/- 7.18 P value NS - -
Graded gait ** (difference from 
baseline)
DFZ: 0.53 +/- 0.62 Placebo: 1.00 +/- 0.89 P value NS - -
Graded stairs ** (difference from 
baseline)
DFZ: -1.79 +/- 4.23 Placebo: 1.27 +/- 1.01 p < 0.01 - -
Graded chair ** (difference from 
baseline)
DFZ: 0.00 +/- 1.00 Placebo: 1.00 +/- 1.41 p < 0.05 - -
Graded Gower ** (difference from 
baseline)
DFZ: 0.12 +/- 0.78 Placebo: 1.00 +/- 1.18 p < 0.02 - -
Other Measures
Time to loss of ambulation DFZ: 33.2 +/- 9 m Placebo: 20.5 +/- 11 m p < 0.005 - -
A dash represents that this outcome measure was not used. MRC = Medical Research Council * For MRC score, MRC index and muscle score 
higher scores are more favorable. ** For Graded scores a lower score is more favorable.
Table 7: Side Effects.
Study (Duration of Follow 
up)
A. Bonifati, 2000 (12 
months)
B. Angelini, 1994 (12 
months)
F. Angelini, 1998 (12 
months)
G. Angelini, 1995 (unclear) N. Brooke, 1996 (12 
months)
Weight Gain
Mean weight increase as a 
percentage of initial weight
DFZ: 9% Pred: 21.3 % p 
< 0.05
Not significant. No 
numeric values given.
Reported as minimal. No 
numeric values given.
Not significantly different 
from the placebo. No 
numeric values given.
DFZ low: 16.8% DFZ high: 
18.3% Pred: 26.7% p < 0.01
Others
Fractures or osteoporosis N = 1 (DFZ) N = 1 (DFZ) Reported as minimal. No 
numeric values.
--
Hirsutism - N = 3 (total) - - -
Cushingoid - N = 2 (total) - - -
Increased Appetite - N = 4 (total) - - -
Behavior Changes - N = 5 (total) - - -
Cataract N = 2 (DFZ) N = 1 
(Prednisone)
- Reported as minimal. No 
numeric values.
--
A dash represents that this side effect was not reported.BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/7
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but at the current time conclusions can not be drawn from
randomized trial sources or meta-analysis.
Quality assessment of randomized controlled trials for the
purpose of systematic review and meta-analysis is difficult
with numerous scales available [15]. In this case the Jadad
scale was chosen as it is a well validated scale [10]. An
indication of allocation concealment was also used as is
suggested in the Cochrane guidelines [16]. The studies
identified for this review were generally of low quality
with an average Jadad score of 1.8 and none commenting
on allocation concealment. This may be primarily due to
the fact that three of the studies, with scores of 2 (Study
N), 1 (Study F) and 0 (Study G) were available only in
abstract form, which is not what the Jadad scale was ide-
ally intended for. Furthermore, the trials were largely pub-
lished prior to the widespread use of CONSORT
guidelines. The quality of reporting of summary statistics
was poor, perhaps even more so than expected from the
Jadad scores. The data presentation and lack of summary
statistics in most cases did not allow the reader a thorough
exploration of the outcomes, and certainly provided no
ability to carry out a meta-analysis. The clinical conclu-
sions from the individual studies included in this review
must be interpreted with the knowledge that some evi-
dence exists to suggest that studies obtaining lower quality
scores may be associated with increased estimate of bene-
fit [17].
As in any systematic review, the limitations in drawing
conclusions are directly dependent on the thoroughness
of reporting in identified studies. Despite an intention to
synthesize the data using meta-analytic techniques this
could not be accomplished due to the inability to obtain
and extract data. In this respect the review is certainly lim-
ited, and any strong conclusions or changes in clinical
practice should be tempered by the realization that the
reporting of trial results was such that summary statistics
were not available or consistently presented. This review
does not use the flow diagram format suggested in the
QUORUM statement as it was felt that with such a small
number of relevant studies using a tabular format would
be more informative. The approach to the reporting of the
review otherwise adheres to the QUORUM statement [9].
Clearly, the most important component needed to deter-
mine the efficacy and safety of DFZ is the publication of
the two large trials identified in this review. If these studies
do not provide a meaningful answer to the efficacy and
safety issues then calls for a further randomized trial
would be necessary. A systematic review of observational
studies, despite being practically and methodologically
more challenging, may help to clarify the situation.
Although randomized controlled trials are considered the
highest quality of study, high quality observational stud-
ies may not over estimate treatment effects to a point of
concern [18].
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